CMS Endorses Increased Dispensing Fees For Inhalation Drugs
This article was originally published in The Pink Sheet Daily
A monthly payment of $55 to $64 per patient is a "reasonable range" for transitional fee payments in 2005, the Centers for Medicare & Medicaid Services tells the Government Accountability Office. A new GAO study highlights variations in inhalation drug dispensing fees and acquisition costs.
You may also be interested in...
CMS is inviting comment on whether a transitional payment rate is needed for inhalation therapies covered under Medicare Part B in 2005
FDA asks Endo to disseminate “corrective messages” to doctors who received the violative promotional materials, which the agency says omit risk information and contain unsubstantiated effectiveness claims.
Studies that look for differences in efficacy among members of the same drug class are only performed when necessary for approval, CDER Office of Medical Policy Director Temple tells DIA. While questioning the introduction of "follow-on" compounds, Temple also highlights AstraZeneca's success in achieving a more optimal dose for Nexium.